ArticleApplied biochemistry and biotechnology2022
In Silico Molecular Docking Approach Against Enzymes Causing Alzheimer's Disease Using Borassus flabellifer Linn.
Article in Applied biochemistry and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 21 citations in OpenAlex.
- Multitarget 8-methoxypsoralens against Alzheimer's disease: extraction, synthesis,Future medicinal chemistry · 2025Article
- Advancing Alzheimer's Therapy: Computational strategies and treatment innovations.IBRO neuroscience reports · 2025Review
- Nanomedicine: A New Frontier in Alzheimer's Disease Drug Targeting.Central nervous system agents in medicinal chemistry · 2025Review
- Fabrication of Hybrid Coated Microneedles with Donepezil Utilizing Digital Light Processing and Semisolid Extrusion Printing for the Management of Alzheimer's Disease.Molecular pharmaceutics · 2024Article
- Unveiling Neuroprotective Potential of Spice Plant-Derived Compounds against Alzheimer's Disease: Insights from Computational Studies.International journal of Alzheimer's disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease is a life-threatening neurodegenerative disorder. About 50 million people across the globe are affected by this disease. At final stages, this disease causes patients to lose cognitive ability, memory, and brain cells to the point of being totally dependent on other individuals for livelihood. The incidence of this disease is increasing across the world in the recent years, making the need of a better drug an urgency. Existing drugs show various side effects and natural sources of medicinal drugs are being explored. In this study, we explore the activity of natural compounds isolated through GC-MS analysis from the haustoria of palmyra palm against two major Alzheimer's disease-causing enzymes, β-secretase and acetylcholinesterase. The binding affinity of these compounds against the target proteins and their pharmacokinetic properties were checked. Among the 37 compounds docked, 5 compounds showed good binding affinity and pharmacokinetic properties. These natural compounds showed a potential as a drug against Alzheimer's disease. Further research is needed to study the synergistic activity of the compounds in live cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.